DC
VRTX icon

Davenport & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Davenport & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103M Sell
207,108
-3,044
-1% -$1.35M 0.51% 59
2026
Q1 		$93.7M Sell
210,152
-1,425
-0.7% -$664K 0.51% 67
2025
Q4 		$95.9M Sell
211,577
-5,707
-3% -$2.46M 0.51% 64
2025
Q3 		$85.3M Sell
217,284
-8,900
-4% -$3.72M 0.45% 75
2025
Q2 		$100M Buy
226,184
+874
+0.4% +$403K 0.55% 61
2025
Q1 		$110M Buy
225,310
+7,242
+3% +$3.37M 0.64% 50
2024
Q4 		$87.6M Sell
218,068
-1,641
-0.7% -$761K 0.5% 71
2024
Q3 		$102M Sell
219,709
-1,816
-0.8% -$872K 0.58% 58
2024
Q2 		$104M Buy
221,525
+2,734
+1% +$1.19M 0.63% 47
2024
Q1 		$91.3M Sell
218,791
-447
-0.2% -$189K 0.56% 59
2023
Q4 		$89.3M Buy
219,238
+103,769
+90% +$38.3M 0.61% 57
2023
Q3 		$40.3M Sell
115,469
-442
-0.4% -$155K 0.3% 99
2023
Q2 		$40.7M Buy
115,911
+101,567
+708% +$34.2M 0.3% 97
2023
Q1 		$4.52M Sell
14,344
-394
-3% -$118K 0.04% 281
2022
Q4 		$4.26M Buy
14,738
+157
+1% +$47.8K 0.03% 272
2022
Q3 		$4.22M Sell
14,581
-6,284
-30% -$1.81M 0.04% 263
2022
Q2 		$5.88M Sell
20,865
-1,405
-6% -$376K 0.05% 222
2022
Q1 		$5.81M Buy
22,270
+1,553
+7% +$369K 0.04% 245
2021
Q4 		$4.55M Buy
20,717
+2,318
+13% +$451K 0.03% 275
2021
Q3 		$3.33M Buy
18,399
+1,272
+7% +$248K 0.02% 302
2021
Q2 		$3.45M Sell
17,127
-124,507
-88% -$26M 0.03% 262
2021
Q1 		$30.4M Buy
141,634
+8,598
+6% +$1.89M 0.29% 94
2020
Q4 		$31.4M Buy
133,036
+131,123
+6,854% +$30.1M 0.31% 91
2020
Q3 		$521K Buy
+1,913
New +$528K 0.01% 453

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Davenport & Co's VRTX Position: Q2 2026 in Review

Davenport & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q2 2026, selling an estimated $1.35M and leaving 207,108 shares worth $103M. The position accounts for 0.51% of the portfolio, ranked #59.

Davenport & Co first reported a position in VRTX in Q3 2020 and has held it in 24 quarters since. The position peaked at $110M in Q1 2025. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Davenport & Co held 207,108 shares of Vertex Pharmaceuticals worth $103M as of Q2 2026.
  • Davenport & Co sold 3,044 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.35M.
  • Vertex Pharmaceuticals made up 0.51% of Davenport & Co's portfolio in Q2 2026, its #59 holding.
  • Davenport & Co first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • Davenport & Co's Vertex Pharmaceuticals position peaked at $110M in Q1 2025.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.